In Brief: SmithKline Beecham Tagamet
Executive Summary
SmithKline Beecham Tagamet: Company will present drug interaction data on cimetidine to joint meeting of FDA's Nonprescription Drug and Gastrointestinal Drugs Advisory Committees during afternoon session of March 27 meeting. The meeting will take place in conference rooms D & E of FDA's Parklawn Building beginning at 1 p.m. SB maintains that the data will show that Tagamet has no clinically significant interactions with other drugs at the proposed OTC dose. Committee concerns about possible interactions resulted in a negative vote on the Rx-to-OTC switch application in July...